Travere Therapeutics(TVTX.US)

Last Updated 19:00:00 ET
longbridge loading

Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo

Tip Ranks·
US
TVTX
+6.40%
Tip Ranks·
US
TVTX
+6.40%

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News

StockTitan·
US
TVTX
+6.40%
StockTitan·
US
TVTX
+6.40%

3 Stocks That May Be Priced Below Their Estimated Value In June 2026

Simplywall·
US
SOLS
+2.33%
US
NBHC
+1.96%
US
TVTX
+6.40%
Simplywall·
US
SOLS
+2.33%
US
NBHC
+1.96%
US
TVTX
+6.40%

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by Brokerages

Market Beat·
US
TVTX
+6.40%
Market Beat·
US
TVTX
+6.40%

BNP Paribas Financial Markets Has $25.44 Million Stock Position in Travere Therapeutics, Inc. $TVTX

Market Beat·
US
TVTX
+6.40%
Market Beat·
US
TVTX
+6.40%

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress | TVTX Stock News

StockTitan·
US
TVTX
+6.40%
StockTitan·
US
TVTX
+6.40%

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

Asian Corporate Newswire·
HK
01952
+1.09%
US
TVTX
+6.40%
Asian Corporate Newswire·
HK
01952
+1.09%
US
TVTX
+6.40%
© 2026 Longbridge｜Disclaimer